A Pilot, Randomised Controlled Study of Ivabradine for Heart Rate Reduction in Critically Ill Patients with Septic Shock

Phase 3

• Conditions: Tachycardia; Critical illness; Septic shock; Cardiovascular - Other cardiovascular diseases; Infection - Other infectious diseases

• Registration Number: ACTRN12618001675213
• Lead Sponsor: Perioperative and Critical Care Research Monash Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-11
• Last Update Posted: 30 September 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

•Patients aged equal and/or older than18 years
•Septic shock as defined as
oHypotension (mean arterial pressure < 65 mmHg) not respon-sive to fluid resuscitation
oRequirements for vasopressors (noradrenaline, vasopressin, metaraminol, phenylephrine)
oInfection of any source
•Sinus tachycardia with heart rate equal or greater than 100

Exclusion Criteria

Exclusion criteria
•Acute heart failure as defined by the presence of cardiogenic shock or cardiogenic pulmonary edema
•Arrhythmmias include Atrial fibrillation (AF)
•Acute hepatic failure as defined by the development of severe acute liver injury with encephalopathy and impaired synthetic function (INR equal or greater than 1.5) in a patient with no pre-existing liver disease
•Decompensated chronic liver disease as defined by the presence of jaundice, ascites, variceal haemorrhage or hepatic encephalopathy in a patient with known liver cirrhosis
•Physician preference
•If the patient expected to die during this admission
•Pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified